Teva Stock Has More Than Doubled in a Year. Where Will It Be in 3 Years?

TEVA has surged 108% over the past year, and the driver is a completed pivot from generic drugs to branded medicines. That shift now anchors the bull case.

Three branded products carry the story: Ajovy, Austedo and Uzedy. Each is posting year-over-year revenue growth in a 40% to 56% range. Those growth rates are the core evidence that the branded mix is scaling, and they explain why the stock has more than doubled.

Analysts project continued gains, but at a slower pace. The cited three-year outlook puts the stock in the low-$50s, a moderate path compared with the past year's 108% move. Interpretation: the easy re-rating appears largely done, and the forecast leans on execution rather than multiple expansion.

The clearest risk is pricing. Austedo faces a 38% price reduction effective January 2027. Because Austedo is one of the three growth engines, that cut targets a meaningful slice of the branded story. Interpretation: the market must weigh whether volume growth can offset a price cut of that size.